SEC Form 4 · accession 0001104659-18-072102
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barbara Y Chan
Officer — See Remarks
Period of report
Dec 6, 2018
Accepted (ET)
Dec 10, 2018 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Dec 6, 2018 | F | 3,313 | $1.28 | D | 19,071 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units.
Remarks
President and Chief Accounting Officer of Aegerion Pharmaceuticals, Inc.